Please ensure Javascript is enabled for purposes of website accessibility

Ocugen Partner Reports Strong Phase 3 Results for Coronavirus Vaccine

By Eric Volkman - Apr 22, 2021 at 8:39AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Bharat Biotech says that its Covaxin demonstrated 100% efficacy against severe COVID-19.

A new coronavirus vaccine candidate could soon be authorized for use, if its excellent clinical results are any indication. Ocugen (OCGN 6.61%) has unveiled the results of a phase 3 clinical trial of the Covaxin vaccine conducted by its co-development partner Bharat Biotech. Most notably, the vaccine demonstrated 100% efficacy against severe COVID-19.

Zooming out, Covaxin's efficacy against mild, moderate, and severe COVID-19 was 78%.

Ocugen made an important and very relevant point about the timing of the study. "The safety and efficacy demonstrated by Covaxin is remarkable because of the prevalence of several variants of the coronavirus circulating at the time of the trial," the company quoted Bruce Forrest, a member of its vaccine scientific advisory board, as saying.

A medical professional using a microscope.

Image source: Getty Images.

All told, 25,800 participants were enrolled in Bharat's trial, which took place in India. The age range was 18 to 91; 2,433 subjects were over the age of 60, and 4,500 had co-morbidities.

Covaxin is being developed with the collaboration of the Indian Council of Medical Research-National Institute of Virology.

Ocugen, a biotech that holds the commercial rights to Covaxin in the U.S. (assuming it is either authorized or approved by the Food and Drug Administration), is very much an outlier in the coronavirus vaccine race. It is known for its development of treatments for rare vision conditions, not vaccines, so it was a bit of a surprise when it leaped into the segment with the Bharat deal in February.

Although such strong results bode well for an FDA nod, Covaxin will be very much a latecomer to this market. The regulator has granted Emergency Use Authorization to three other vaccines, two of which (Moderna's mRNA-1273 and Pfizer/BioNTech's BNT162b2) have been widely and successfully administered throughout the country for months.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ocugen, Inc. Stock Quote
Ocugen, Inc.
OCGN
$2.42 (6.61%) $0.15
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$52.31 (-0.23%) $0.12
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$149.95 (4.97%) $7.10
BioNTech SE Stock Quote
BioNTech SE
BNTX
$157.50 (5.63%) $8.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.